Recent market pressure could worsen, but that won't stop these successful businesses from raising their dividend payouts.If you're more nervous than usual about buying stocks these days you're not alone. From July 16 through Aug. 2, the benchmark S&P 500 index fell about 5.7% from its all-time high.The recent stock market drop is still a few points shy of an official market correction, but it's enough to make everyday investors think twice before purchasing risky growth stocks.If fear of a market correction ...

GeorgePeters Introduction Things aren't going so well anymore. The AI-fueled tech rally has stalled, and all eyes are now on the "real" economy, which is showing some serious cracks. The just-released unemployment numbers, for example, came in much lower than expected, with nonfarm payrolls indicating just 114 thousand new jobs in July. The prior month's gain was revised from 206 thousand to 179 thousand. The unemployment rate rose to 4.3%, 20 basis points higher than expected. Bloomberg These numbers c ...

On Jul 25, AbbVie (ABBV) announced strong second-quarter results. AbbVie beat estimates for both earnings and sales. Earnings declined 8.9% year over year due to costs related to recent acquisitions and deals. Sales rose 5.6% year over year on an operational basis.AbbVie lost patent protection for its blockbuster immunology drug Humira in the United States in January 2023 and in the EU in 2018. Sales of Humira are declining due to loss of exclusivity and biosimilar erosion. However, in the second quarter, s ...

Cerevel's clinical-stage assets complement AbbVie's emerging neuroscience pipeline and leading on-market brands in psychiatry, migraine and Parkinson's diseaseEmraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophreniaCerevel is a strong strategic fit for AbbVie and has potential to meaningfully impact revenue into the next decadeAbbVie reaffirms previously issued 2024 full-year adjusted diluted EPS guidance range of $10.71-$10.9 ...

patpitchaya/iStock via Getty Images Introduction When investing one should always have a long-term outlook. Day or short-term trading can give you potential gains, but this will likely end badly if you continue with this strategy. To me, this is similar to going to a casino and hitting a few winning hands on the blackjack table. Question always is: "How long will this last?" No one knows, but it surely won't last forever. That's why you should play the long game, especially when investing in stocks that ...

Understanding companies’ fundamentals is vital for evaluating top stocks to buy. It helps one to make sharp investment decisions based on financial health, growth potential and competitive advantages. The below stocks remain undervalued and are industry leaders set for growth post-earnings season, making them ideal candidates to capitalize on the next major bull run.The first company excels in communication services, with strategic investments driving future growth. Meanwhile, the second company, in semicon ...

Growth stocks, known for rapid expansion and solid market positions, have outperformed for years. Despite not being market leaders yet, they possess the potential to dominate. For long-term investors seeking high upside potential, these growth stocks are compelling choices. Although riskier than big names, their strong fundamentals and competitive edge can drive significant gains. Despite numerous S&P 500 companies reporting losses, top performers tend to outperform this index and others. However, performan ...

Join the seven million loyal Allē Members in celebrating the second annual JUVÉDERM® Day on August 21, 2024Members receive an exclusive gift card offer and a chance to win $10,000*IRVINE, Calif., July 30, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the return of JUVÉDERM® Day on Wednesday, August 21. After a successful first year, JUVÉDERM® Day is back with limited time offers, savings, and exclusive deals through Allē, the Allergan Aesthetics loyalty rewards pr ...

Morsa Images/DigitalVision via Getty ImagesSince my last article was published on April 29, AbbVie's share price (NYSE:ABBV) has risen more than 16%, hitting new multi-year highs. This article will focus not only on the company's Q2 2024 financial results but also on other factors that make me believe it is becoming an increasingly attractive stock among Big Pharma despite the lack of significant progress in developing its oncology franchise. AbbVie's Q2 2024 financial results were beyond praise AbbVie' ...

High-yield dividend stocks are attractive investment options as they provide regular payouts regardless of market performance. Understanding dividend yield, which is a ratio showing annual dividend income per dollar invested, is crucial for comparing investments.The yield, expressed as a percentage of the current price, indicates the annual return on investment at the purchase price. Reinvesting dividends can significantly enhance returns due to compounding.Divide the annual dividend per share by the share ...